Quantcast

Latest KaloBios Pharmaceuticals Inc. Stories

2014-08-14 08:29:14

-- Anti-EphA3 Agents Inhibit Tumor Growth by Disrupting or Destroying the Tumor Microenvironment: Malignant Stem Cells, Stromal Cells, and New Tumor Vasculature -- SOUTH SAN FRANCISCO, Calif., Aug. 14, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and...

2014-05-08 16:26:54

-- Provides Update on Clinical Programs and Timelines -- SOUTH SAN FRANCISCO, Calif., May 8, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for the first quarter of 2014 and provided an update on its current clinical programs and timelines. http://photos.prnewswire.com/prnvar/20130225/MM66380LOGO Development Program Updates KB001-A Enrollment in the Phase 2 study in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa)...

2014-05-06 16:32:39

SOUTH SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company's board of directors has elected Ted W. Love, M.D., as the Chairman, effective May 1, 2014. Dr. Love succeeds James I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board since 2001. Dr. Healy recently informed KaloBios that in light of the company's public offering in 2013 and his other present and potential...

2014-04-03 20:22:32

SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference: -- 13(th) Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - 11:50AM US ET (8:20AM - 8:50AM US PT) Presentations will include overviews of the company's KB001-A development program to...

2014-03-13 16:28:03

SOUTH SAN FRANCISCO, Calif., March 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013. Fiscal 2013 Accomplishments Key corporate accomplishments during fiscal 2013 included: -- KB001-A - Received orphan drug status for KB001-A from the U.S. Food and Drug Administration and the European Medicines Agency...

2014-03-10 16:32:54

BioCentury Conference Presentation to be Webcast SOUTH SAN FRANCISCO, Calif., March 10, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences: -- 26(th) Annual ROTH ConferenceWednesday, March 12, 2014 in Laguna Niguel, California8:00 - 8:30 AM Pacific Time -- BioCentury's Future Leaders in the Biotech Industry ConferenceFriday, March 28, 2014 in New...

2014-02-11 08:32:20

-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb. 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered(®) monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2...

2014-02-05 20:26:52

SOUTH SAN FRANCISCO, Calif., Feb. 5, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: -- 16(th) Annual BIO CEO & Investor ConferenceTuesday, February 11, 2014 in New York City8:30 AM Eastern Time (5:30 AM Pacific Time) -- Leerink Global Healthcare Conference 2014Thursday, February 13, 2014 in New...

2014-01-29 16:28:39

Study Does Not Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif., Jan. 29, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV(1) (a measurement of pulmonary...

2014-01-13 08:28:07

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the presentation of epidemiological research sponsored by Sanofi Pasteur, KaloBios' exclusive licensee for KB001-A, estimating the incidence of Pseudomonas aeruginosa Ventilator Associated Pneumonia (Pa-VAP) in at-risk patients requiring intubation and mechanical ventilation. The presentation also describes the risk factors among patients with VAP and Pa-VAP. The new...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related